Respiratory Syncytial Virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms. Most people recover in a week or two, but RSV can be serious, especially for infants and older adults.
Moderna is taking a similar approach to a vaccine for RSV as they took for their historic and ground-breaking COVID-19 Vaccine. This experimental vaccine will use synthetic mRNA that contains the signature spike protein of RSV. The intent is that the mRNA will help instruct the body to produce proteins to prevent or fight RSV.
Don’t see your question listed here?Contact Us